{{Rsnum
|rsid=1443548
|Gene=SLC6A5
|Chromosome=11
|position=20601496
|Orientation=plus
|GMAF=0.2107
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC6A5
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 58.4 | 34.5 | 7.1
| HCB | 62.0 | 32.8 | 5.1
| JPT | 61.9 | 31.9 | 6.2
| YRI | 82.9 | 15.8 | 1.4
| ASW | 66.7 | 31.6 | 1.8
| CHB | 62.0 | 32.8 | 5.1
| CHD | 61.5 | 32.1 | 6.4
| GIH | 77.2 | 18.8 | 4.0
| LWK | 67.3 | 29.1 | 3.6
| MEX | 69.0 | 24.1 | 6.9
| MKK | 60.9 | 36.5 | 2.6
| TSI | 58.8 | 36.3 | 4.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=20859245
|Title=Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol
}}

{{GET Evidence
|gene=SLC6A5
|aa_change=Phe124Ser
|aa_change_short=F124S
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1443548
|overall_frequency_n=8591
|overall_frequency_d=10758
|overall_frequency=0.798568
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=76
|n_articles=0
|n_articles_annotated=0
|gene_in_genetests=Y
|genetests_reviewed=Y
|nblosum100=5
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}